Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study to Evaluate the Safety and Efficacy of BCT301 Cell Injection in Patients With Refractory/Recurrent IgG4-Related Disease

NCT07793903 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT07793903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07793903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study to Evaluate the Safety and Efficacy of BCT301 Cell Injection in Patients With Refractory/Recurrent IgG4-Related Disease
Lead sponsor
Peking University Third Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
February 28, 2030
Enrollment
6 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

igg4-related disease